Dyadic Logo Current.jpg
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
February 06, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Dyadic Logo Current.jpg
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
January 02, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Icosavax_Logo.jpg
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
December 12, 2023 02:05 ET | Icosavax, Inc.
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Icosavax_Logo.jpg
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
December 12, 2023 02:00 ET | Icosavax, Inc.
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Icosavax_Logo.jpg
Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 14, 2023 16:05 ET | Icosavax, Inc.
- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023...
FFF Enterprises Inc.
FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus (RSV) Products to Its Comprehensive, Expanding Portfolio
September 13, 2023 13:34 ET | FFF Enterprises.com
TEMECULA, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with...
Icosavax_Logo.jpg
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 16:05 ET | Icosavax, Inc.
- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept...
Icosavax_Logo.jpg
Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential
August 08, 2023 16:05 ET | Icosavax, Inc.
- In new data from Icosavax’s IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) - ...
Icosavax_Logo.jpg
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
June 20, 2023 08:00 ET | Icosavax, Inc.
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) --...
Icosavax_Logo.jpg
Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 16:05 ET | Icosavax, Inc.
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term...